Patrys PAB.AX · AUD

Its shares trade on ASX under the ticker PAB.AX. It has been listed since 13 July 2007. In the fiscal year to 30 June 2026, it reported revenue of A$8,985 and a net loss of A$3.4m. At that date it held total assets of A$11.1m and shareholders' equity of A$10.2m.

Patrys Ltd. engages in the commercialisation of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-07-13. The firm is engaged in conducting research and development activities in the biopharmaceutical sector. The firm's products include PAT-SM6, PAT-LM1 and PAT-SC1. PAT-SM6 is a natural human antibody that binds to multiple types of cancer, including solid tumors, such as melanoma, breast, colon and pancreatic, as well as blood-based cancers, such as multiple myeloma. PAT-SM6 has completed its Phase I clinical trials for melanoma and Phase I/IIa clinical trials for multiple myeloma. PAT-LM1 is a natural human antibody that can be used for treatment of multiple types of cancer, with potency against colon, lung, breast, ovary and pancreatic cancers. PAT-LM1 is in pre-clinical stage of its study. The company offers 3E10 Deoxymab, a lupus autoantibody. The company is toxic to cancer cell that has deficiencies in deoxyribonucleic acid repair.

Figures and description from our data supplier, not checked against the company's own report.

• Dr. Charmaine GittlesonChairman of the Board, since 2022
• Dr. James CampbellChief Executive Officer, Managing Director, Executive Director, since 2014A$718,035
• Mr. Michael StorkNon-Executive Deputy Chairman of the Board, since 2007A$5,002
• Ms. Valentina DubljevicVice President - Research and Development
• Dr. Rebecca TunstallVice President - Corporate Development
• Dr. Deanne GreenwoodVice President - Business Development & Intellectual PropertyA$146,291
• Mr. Stefan RossCompany Secretary, since 2021

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.